Đang chuẩn bị liên kết để tải về tài liệu:
Abiraterone acetate plus prednisone for the Management of Metastatic CastrationResistant Prostate Cancer (mCRPC) without prior use of chemotherapy: Report from a large, international, real-world retrospective cohort study

Không đóng trình duyệt đến khi xuất hiện nút TẢI XUỐNG

With the recent introduction of novel treatment options, real-world data from patients with metastatic castration-resistant prostate cancer (mCRPC) are required to better understand the impact on routine clinical practice. | Abiraterone acetate plus prednisone for the Management of Metastatic CastrationResistant Prostate Cancer mCRPC without prior use of chemotherapy Report from a large international real-world retrospective cohort study

TÀI LIỆU LIÊN QUAN

The LACOG-0415 phase II trial: Abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels

Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: Results from a prospective observational study (CAPRO)

Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: An Italian multicenter “real life” study

A high neutrophil-to-lymphocyte ratio is a poor prognostic factor for castrationresistant prostate cancer patients who undergo abiraterone acetate or enzalutamide treatment

Đánh giá kết quả điều trị Abiraterone Acetate + Prednisolon ung thư tuyến tiền liệt di căn kháng cắt tinh hoàn

Abiraterone acetate plus prednisone for the Management of Metastatic CastrationResistant Prostate Cancer (mCRPC) without prior use of chemotherapy: Report from a large, international, real-world retrospective cohort study

Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: Long term outcome of the Temporary Authorization for Use programme in France

Corticosteroid switch from prednisone to dexamethasone in metastatic castrationresistant prostate cancer patients with biochemical progression on abiraterone acetate plus prednisone

A prospective phase-II trial of biweekly docetaxel plus androgen deprivation therapy in patients with previously-untreated metastatic castration-naïve prostate cancer
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.